Premium
Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease
Author(s) -
Peng Jiang Chen,
Shen Jun,
Ran Zhi Hua
Publication year - 2014
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12193
Subject(s) - medicine , inflammatory bowel disease , tumor necrosis factor alpha , disease , crohn's disease , clinical trial , inflammatory bowel diseases , biologic agents , intensive care medicine , tumor necrosis factor α , infliximab , immunology
Anti‐tumor necrosis factor (TNF)‐α agents emerge as the hot spot in the last decade for treating patients with inflammatory bowel disease ( IBD ). The effect of anti‐ TNF ‐α agents is satisfactory; however, some patients fail to achieve clinical response. Fortunately, in recent years, great efforts have been made and multiple novel therapies have been developed in the treatment for IBD . In this article, we aim to introduce anti‐ TNF ‐α drugs as well as other novel treatments currently undergoing clinical trials for IBD .